Emerging NIPT Market in Asia Pacific
Non-Invasive Prenatal Testing (NIPT) has catapulted the growth in the molecular diagnostics market. In the US, where the test was initially launched, the market is expected to grow at a CAGR of 49% during 2012-2017. This growth can be attributed to several factors, foremost of all being its high acceptance amongst high-risk pregnant mothers. The tests have a more than 99% sensitivity of detecting Down’s syndrome and completely eliminate the risk associated with invasive prenatal tests like CVS and Amniocentesis, gaining them instant popularity amongst the consumers.
But due to a restrictive potential population base in the US, which is estimated at around 700,000, players based in the region were quick to expand beyond their base and launch the tests in the EU and selective regions of Asia-Pacific (APAC). For our study, we have selected the APAC region since it represents a highly underpenetrated market with immense potential for growth.
APAC houses almost a third of global population. According to our report, “Emerging NIPT Market in Asia Pacific” there are around 1 Million potential patients in the region representing a greater than US$ 1 Billion market. The major market in this region lies in Japan, where the rapidly ageing population has created a huge, untapped potential market for players. China is another major region where two local players; BGI and Berry Genomics are expected to collectively accession around 100,000 tests in 2013 alone.
The report covers exhaustive analysis of the potential population for NIPT tests in each region. Different scenarios have been explored in line with the regulatory environment in a given region. Detailed description of current market scenario highlighting the currently available tests, business model followed by players, cost of their tests, number of tests accessioned by them etc. has also been provided.
Besides, test volumes and markets till 2018 have been forecasted. The forecast is conducted on the basis of co-relation and judgmental analysis, which is carried out after carefully studying key factors including rise in penetration, expansion in distributor network, rising popularity and awareness amongst consumers, regulatory scenario and various other drivers and challenges.
Overall, the report presents optimum information and transparent research outlook that highlights opportunities and potentials in the nascent APAC NIPT sector.
But due to a restrictive potential population base in the US, which is estimated at around 700,000, players based in the region were quick to expand beyond their base and launch the tests in the EU and selective regions of Asia-Pacific (APAC). For our study, we have selected the APAC region since it represents a highly underpenetrated market with immense potential for growth.
APAC houses almost a third of global population. According to our report, “Emerging NIPT Market in Asia Pacific” there are around 1 Million potential patients in the region representing a greater than US$ 1 Billion market. The major market in this region lies in Japan, where the rapidly ageing population has created a huge, untapped potential market for players. China is another major region where two local players; BGI and Berry Genomics are expected to collectively accession around 100,000 tests in 2013 alone.
The report covers exhaustive analysis of the potential population for NIPT tests in each region. Different scenarios have been explored in line with the regulatory environment in a given region. Detailed description of current market scenario highlighting the currently available tests, business model followed by players, cost of their tests, number of tests accessioned by them etc. has also been provided.
Besides, test volumes and markets till 2018 have been forecasted. The forecast is conducted on the basis of co-relation and judgmental analysis, which is carried out after carefully studying key factors including rise in penetration, expansion in distributor network, rising popularity and awareness amongst consumers, regulatory scenario and various other drivers and challenges.
Overall, the report presents optimum information and transparent research outlook that highlights opportunities and potentials in the nascent APAC NIPT sector.
1. ANALYST VIEW
2. RESEARCH METHODOLOGY
3. INTRODUCTION
3.1 MaterniT21 PLUS
3.2 Verifi
3.3 Panorama
3.4 Harmony
3.5 NIFTY
3.6 Bambni
3.7 Association of Down’s syndrome Risk to Fetus with Mother’s Age
4. ASIA-PACIFIC NIPT MARKET OUTLOOK TO 2018
4.1 Australia
4.1.1 Market Potential
4.1.2 Market Overview
4.1.3 Regulatory Scenario
4.2 China
4.2.1 Market Potential
4.2.2 Market Overview
4.2.3 Regulatory Scenario
4.3 Japan
4.3.1 Market Potential
4.3.2 Market Overview
4.3.3 Regulatory Scenario
4.4 India
4.4.1 Market Potential
4.4.2 Regulatory Scenario
2. RESEARCH METHODOLOGY
3. INTRODUCTION
3.1 MaterniT21 PLUS
3.2 Verifi
3.3 Panorama
3.4 Harmony
3.5 NIFTY
3.6 Bambni
3.7 Association of Down’s syndrome Risk to Fetus with Mother’s Age
4. ASIA-PACIFIC NIPT MARKET OUTLOOK TO 2018
4.1 Australia
4.1.1 Market Potential
4.1.2 Market Overview
4.1.3 Regulatory Scenario
4.2 China
4.2.1 Market Potential
4.2.2 Market Overview
4.2.3 Regulatory Scenario
4.3 Japan
4.3.1 Market Potential
4.3.2 Market Overview
4.3.3 Regulatory Scenario
4.4 India
4.4.1 Market Potential
4.4.2 Regulatory Scenario
LIST OF FIGURES:
Figure 4-1: Australia - Number of Births (‘000), 2013-2018
Figure 4-2: Australia - Number of Births by Mother’s Risk of Down’s syndrome (%), 2011
Figure 4-3: Australia - Potential Market in Three Different Scenarios (US$), 2013
Figure 4-4: Australia - NIPT Market (Million US$), 2013-2018
Figure 4-5: Australia - NIPT Market (Volume ‘000), 2013-2018
Figure 4-6: China - Number of Births (Million), 2013-2018
Figure 4-7: China - Potential Market in Two Different Scenarios (US$), 2012
Figure 4-8: China - NIPT Market (Million US$), 2013-2018
Figure 4-9: China - NIPT Market (Volume ‘000), 2013-2018
Figure 4-10: Japan - Number of Births (‘000), 2013-2018
Figure 4-11: Japan - Number of Births by Mother’s Risk of Down’s syndrome (%), 2010
Figure 4-12: Japan - Potential Market in Two Different Scenarios (US$), 2013
Figure 4-13: Japan - NIPT Market (Million US$), 2013-2018
Figure 4-14: Japan - NIPT Market (Volume ‘00), 2013-2018
Figure 4-15: India - Number of Births (Million), 2013-2018
Figure 4-1: Australia - Number of Births (‘000), 2013-2018
Figure 4-2: Australia - Number of Births by Mother’s Risk of Down’s syndrome (%), 2011
Figure 4-3: Australia - Potential Market in Three Different Scenarios (US$), 2013
Figure 4-4: Australia - NIPT Market (Million US$), 2013-2018
Figure 4-5: Australia - NIPT Market (Volume ‘000), 2013-2018
Figure 4-6: China - Number of Births (Million), 2013-2018
Figure 4-7: China - Potential Market in Two Different Scenarios (US$), 2012
Figure 4-8: China - NIPT Market (Million US$), 2013-2018
Figure 4-9: China - NIPT Market (Volume ‘000), 2013-2018
Figure 4-10: Japan - Number of Births (‘000), 2013-2018
Figure 4-11: Japan - Number of Births by Mother’s Risk of Down’s syndrome (%), 2010
Figure 4-12: Japan - Potential Market in Two Different Scenarios (US$), 2013
Figure 4-13: Japan - NIPT Market (Million US$), 2013-2018
Figure 4-14: Japan - NIPT Market (Volume ‘00), 2013-2018
Figure 4-15: India - Number of Births (Million), 2013-2018
LIST OF TABLES:
Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
Table 3-2: MaterniT21 PLUS Test Validation Results
Table 3-3: Verifi Test Validation Results
Table 3-4: Panorma Test Validation Results
Table 3-5: Harmony Test Validation Results
Table 3-6: NIFTY Test - Summary of Phase I Clinical Trial
Table 3-7: NIFTY Test - Summary of Phase II Clinical Trial
Table 3-8: Bambni Test - Summary of Phase I Clinical Trial
Table 3-9: Bambni Test - Summary of Phase II Clinical Trial
Table 3-10: Risk of Down’s syndrome with Rise in Maternal Age
Table 4-1: Australia - Number of Births by Age of Mother (2011)
Table 4-2: Australia NIPT Market Landscape - Players; Australian Partner; Cost per Test
Table 4-3: China NIPT Market Landscape - Players; Cost per Test
Table 4-4: Japan - Number of Births by Age of Mother (2010)
Table 4-5: Japan NIPT Market Landscape - Player; Cost per Test
Table 3-1: Comparison of Features of Key NIPT Tests in APAC NIPT Market
Table 3-2: MaterniT21 PLUS Test Validation Results
Table 3-3: Verifi Test Validation Results
Table 3-4: Panorma Test Validation Results
Table 3-5: Harmony Test Validation Results
Table 3-6: NIFTY Test - Summary of Phase I Clinical Trial
Table 3-7: NIFTY Test - Summary of Phase II Clinical Trial
Table 3-8: Bambni Test - Summary of Phase I Clinical Trial
Table 3-9: Bambni Test - Summary of Phase II Clinical Trial
Table 3-10: Risk of Down’s syndrome with Rise in Maternal Age
Table 4-1: Australia - Number of Births by Age of Mother (2011)
Table 4-2: Australia NIPT Market Landscape - Players; Australian Partner; Cost per Test
Table 4-3: China NIPT Market Landscape - Players; Cost per Test
Table 4-4: Japan - Number of Births by Age of Mother (2010)
Table 4-5: Japan NIPT Market Landscape - Player; Cost per Test
